CMS Contract Year 2027 Medicare Advantage Final Rule Updates (CMS-4208-F3/CMS-4212-F) 

Overview 

On April 2, 2026, CMS released the Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-F3/CMS-4212-F), which will become effective on June 1, 2026 and will be applicable to coverage beginning January 1, 2027. This is an annual CMS regulatory update, the purpose of which is to address amendments to the regulations governing the Medicare Advantage and Medicare Prescription Drug Programs (Medicare Parts C and D respectively).  

Key Updates 

I. Major Changesto Star Ratings 

CMS has finalized a significant recalibration of the Medicare Advantage and Part D quality program. Enhancements include the removal of long-standing Star Rating measures that CMS believes have become “topped out” or less meaningful, with greater emphasis being placed on outcomes and sustained performance.  

Notably, CMS did not finalize some of the proposed health equity reward concepts; however, the Agency did keep the current structure more intact than the industry had expected. The direction of this Agency policy favors outcomes, member experience, and sustained quality performance over process metrics. This matters because MA Plans will likely react by shifting quality investments and provider incentive structures, resulting in the need for value-based provider groups to review and potentially realign quality priorities and reporting. 

It is also noteworthy that CMS has stepped away from the proposed Health Equity Index Reward in Star Rating. The Agency has not abandoned the policy of health equity but appears to be signaling caution about how “equity” is operationalized in payment systems. 

With MA Plan revisions likely to focus on value-based contracts, shared savings methodologies, quality bonus structures, and provider scorecards, high-performing provider groups are encouraged to assess protocols and policies involving preventative screening completion, behavioral health follow-up, medication adherence, and general member experience and access. 

II. ProgramSimplification and De Regulation 

CMS also used this Final Rule as the conduit to reduce some administrative burden by rescinding or simplifying select regulatory requirements, which the Agency framed as cost and operational complexity reduction efforts specifically for MA plans. 

In addition to the changes to the Star Ratings, CMS also finalized guardrails around supplemental benefits administration, including clarifications for special supplemental benefits (ie. Plans offering food, transportation, care transition assistance, utility assistance, or flex-card benefits) and debit-card benefit administration. The result of which will likely force MA Plans to make significant operational changes and require tighter eligibility controls. 

CMS also enhanced protections for enrollees affected by provider/facility terminations by expanding the Special Enrollment Period (SEP). Enrollees will now be able to more readily access a SEP without requiring CMS to deem the network change as “significant.” These enhancements are intended to result in more flexibility for beneficiaries to switch plans when a physician or facility exits a network and will likely result in heightened notification and compliance obligations for MAOs. Providers are encouraged to assess their patient retention risk if a practice or entire health system is considering termination of an MA account. Because provider network disruptions will now have faster enrollment consequences, payer-provider contracting decisions will be much more visible to beneficiaries and may increase provider leverage during payer contracting. 

CMS has also finalized updates to Third-Party Marketing Organization (TPMO) rules and communication requirements, including adjustments to disclaimer and oversight requirements. These Agency enhancements are not expected to impact providers but will directly affect the oversight of Medicare brokers and agents, call centers, and MA compliance teams and are expected to focus on updates/prohibitions to scripts, disclosures, retention policies, and enrollment workflows. 

III. Part D Redesign 

The Part D program redesign is by far the biggest financial implication of this annual update, with CMS finalizing the regulatory framework implementing the major prescription drug changes stemming from the Biden era Inflation Reduction Act.  

This Rule continues to eliminate the long-standing Coverage Gap Discount Program (CGDP), replacing it with the formal codification of the Manufacturer Discount Program. This Program requires brand-name pharmaceutical manufacturers to provide discounts directly to beneficiaries at the point of sale once out-of-pocket spending meets the Program threshold. Discounts on phase-in pharmaceuticals are expected to range anywhere from 1% up to 20% between 2026 and 2031. 

In order to stay compliant with this Program, both Prescription Drug Plans (PDPs) and Medicare Advantage Prescription Drug Plans (MA-PDPs) will be expected to have formulary, actuarial bid, and pharmacy network adjustments, while providers may see shifts in utilization management and preferred drug placement. 

IV. Future Policies and Agency Direction

CMS has explicitly framed this Final Rule around maximizing value for beneficiaries and taxpayers, using the CY 2027 Final Rule not only to finalize policies, but to telegraph where they anticipate Medicare Advantage (Medicare Part C) and Medicare Part D are heading over the next 3-5 years. Signals throughout this rule point to greater accountability, simpler quality measurements, payment accuracy, and stronger scrutiny of benefit value versus expansion.  

The impact for providers (ie. physicians, hospitals, health systems, post-acute providers and provider groups participating in Medicare Advantage) is less about updates to fee-for-service reimbursement and more about being alert to changes in network strategy, quality incentives, and documentation requirements, as well as beneficiary retention and administrative burden shifts. For MA Plans, operational readiness will be critical. MAOs will need to focus on bid and actuarial strategies, Part D operational readiness, Star Rating redesign, marketing compliance updates, updating member communications, and general provider network stability. 

Key Take-Aways 

Final Rule CMS-4212-F underscores the Agency’s continued multi-year shift toward greater beneficiary protections, health care affordability and plan protections. With a focus on drug affordability, enhanced quality measurements, enrollment protections, and strengthened operational oversight, the emphasis for MAOs has become member outcomes and compliance execution. 

With CMS moving Medicare Advantage toward a more regulated, outcomes-driven, financially accountable model where plans must demonstrate real value, the thematic focus for both providers and MA Plans include: 

Payment accuracy over coding intensity; outcomes over process metrics; supplemental benefits with measurable ROI; enhanced oversight of beneficiary protections and access and greater accountability for both Plans and providers. 

On The Radar 

Proposed Congressional Legislation Directly Impacting MA Plans: On April 20, 2026 a bipartisan group from the U.S. House of Representatives proposed legislation directly aimed at strengthening Medicare Advantage plan oversight to improve timeliness and quality of care. H.R. 8375 entitled “Medicare Advantage Improvement Act of 2026” (MAIA), is focused on reforming how MA Plans operate, particularly around prior authorization, provider payments, and transparency. Similar in goals and intent to CMS-4201-F, this Bill attempts to reform the Medicare Advantage program by curbing restrictive utilization practices and forcing private MA plans to adhere to traditional Medicare coverage criteria. 

This proposed bill seeks to reduce delays in medically necessary care, adding guardrails and transparency around MA plan prior authorization decisions. It also establishes or in some cases strengthens expectations for timely reimbursement to providers, and it also addresses retrospective denials and recoupment practices where MA plans seek repayment after services have already been delivered. If passed, this Bill would also require greater reporting and clearer rules around utilization management and payment practices and is intended to improve access to medically necessary services for Medicare beneficiaries enrolled in MA plans. 

For health care providers, this Bill would significantly reduce the administrative burden tied to prior authorizations and improve cash flow and denials management, while it could also impact MA appeals and audit exposure, and it could result in MA plan-provider contracting leverage. H.R. 8375 has only been introduced in the House and has been referred for Congressional consideration. It has not yet become law, and as such, we are all encouraged to stay alert and vigilant to the status of this highly impactful Bill. 

Major Health Insurers Act on Industry-Wide Commitment: On April 24, 2026, several major health insurers announced they were advancing efforts to standardize prior authorization requirements, keeping to their June 2025 commitment to HHS to streamline, simplify, and reduce prior authorizations. Two specific industry groups, America’s Health Insurance Plans (AHIP) and the Blue Cross Blue Shield Association, are spearheading these changes with national entities including Aetna, Cigna, and UHC actively taking steps to implement standardization policies on a rolling basis.  

Over 60 major insurers committed to the June 2025 pledge, which included an effective January 1, 2026 promise to reduce the procedures requiring prior authorization and begin honoring prior authorization approvals for 90-days when patients switch plans. It also included the commitment to clearly communicate denial explanations and appeal options to patients. The recent announcement has resulted in a six-pronged pledge that includes the following key improvements: 

• Standardization of Electronic Prior Authorization Requests – By January 1, 2027
• Reduce the Number and Scope of Services Requiring a Request
• Accelerate the Response Times to Provide Real-Time Decisions – By January 1, 2027
• Boost Continuity of Care When Patients Change Plans
• Clear Explanation of Denials and Instructions for Appeal
• Ensure ALL Denials are Based on a Medical Necessity Review by Licensed, Qualified Clinician

While this industry self-standardization of the prior authorization process is still in its earliest stages, it remains voluntary, which allows payers wide latitude with regard to compliance. Given that there is no oversight or target alignment goals, providers may remain reluctant to anticipate improvements. To that end, this activity is worth keeping a vigilant eye and ear open for any activity that may have a direct impact on providers. 

For more information regarding the Final Rule, CMS has developed a Fact Sheet for FY 2027 Medicare Advantage and Medicare Prescription Drug Final Rule (CMS-4208-F3/CMS-4212-F), highlighting the updates and offering additional insight into Agency intent.